US biotech firm ArQule (Nasdaq: ARQL) closed 17% higher on Tuesday at $3.16 after announcing that it was to receive an upfront payment of $10 million and up to $326 million in regulatory and commercial milestones as part of a licensing deal with Basilea Pharmaceutica (SIX: BSLN).
The commercial stage Swiss biopharma has paid for rights to develop and commercialize the pan-fibroblast growth factor receptor (FGFR) derazantinib everywhere in the world except for China, Hong Kong, Macau and Taiwan, where the Roivant Sciences subsidiary Sinovant Sciences holds the rights.
“This transaction underscores our continued commitment to expand our R&D portfolio"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze